Results 311 to 320 of about 137,002 (346)

Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation.

Cell Metabolism, 2023
Chi Kin Wong, Brent A. McLean, L. Baggio, J. Koehler, Rola Hammoud, N. Rittig, Julian M Yabut, Randy J. Seeley, Theodore J Brown, D. J. Drucker   +9 more
semanticscholar   +1 more source

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

Ca-A Cancer Journal for Clinicians, 2023
Laura A Huppert, Hope S Rugo
exaly  

Chimeric antigen receptor T‐cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice

Ca-A Cancer Journal for Clinicians, 2023

exaly  

Critical care management of chimeric antigen receptor T‐cell therapy recipients

Ca-A Cancer Journal for Clinicians, 2022
Alexander Shimabukuro-Vornhagen, Boris Böll, Victoria Metaxa   +2 more
exaly  

Breast Cancer Statistics, 2022

Ca-A Cancer Journal for Clinicians, 2022
Hyuna Sung, Kimberly D Miller, Rebecca L Siegel   +2 more
exaly  

Current treatment and recent progress in gastric cancer

Ca-A Cancer Journal for Clinicians, 2021
Smita S Joshi, Brian D Badgwell
exaly  

Glucagon Like Peptide 1 Receptor

2018
openaire   +2 more sources

The physiology of glucagon-like peptide 1.

Physiological Reviews, 2007
J. Holst
semanticscholar   +1 more source

A review of cancer immunotherapy toxicity

Ca-A Cancer Journal for Clinicians, 2020
Lucy Boyce Kennedy
exaly  

Treatment of muscle‐invasive and advanced bladder cancer in 2020

Ca-A Cancer Journal for Clinicians, 2020
Vaibhav G Patel, William K Oh, Matthew D Galsky   +2 more
exaly